Grifols’ Xembify (20% SC Immunoglobulin) Receives FDA’s Approval for the Treatment of Primary Immunodeficiencies

Shots:

• The approval of Xembify reflects Grifols’ commitment to R+D+i and innovation which enables the company to develop new therapies and enhances its Bioscience Division’s product portfolio
• Grifol is working with regulatory authorities to seek approval in Canada, Europe and other global markets and plans to launch the Xembify in the US in Q4’19
• Xembify is a 20% SC Ig solution indicated to treat patients with primary humoral immunodeficiency (PI) aged ≥ 2yrs. Additionally, Grifols’ GamaSTAN & HyperRAB has received FDA’s approval in 2018 for providing protection against hepatitis A and measles & to treat patients exposed to rabies virus

Click here to read full press release/ article | Ref: Grifols | Image: The Corner